<p>鐵木藥業公司（NASDAQ:IRWD - 獲取免費報告）週四股價下跌了 5%。該股最低交易價為 3.57 美元，最後交易價為 3.5450 美元。在午盤交易中，約有 366,023 股被交易，較日均交易量 2,568,063 股下降了 86%。該股此前收盤價為 3.73 美元。</p>
<h2>華爾街分析師預測增長</h2>
<p>幾位股票分析師最近對該股發表了看法。華爾街 Zen 在 8 月 9 日的報告中將鐵木藥業的評級從 “持有” 上調至 “強烈買入”。Zacks Research 在 11 月 4 日的研究報告中將鐵木藥業的評級從 “強烈買入” 下調至 “持有”。富國銀行在 11 月 11 日的研究報告中將鐵木藥業的目標價從 1.00 美元上調至 3.00 美元，並給予該股 “等權重” 評級。最後，Weiss Ratings 在週一的研究報告中重新發布了對鐵木藥業的 “賣出（d）” 評級。一位股票研究分析師給予該股 “買入” 評級，六位分析師給予 “持有” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股的平均評級為 “持有”，平均目標價為 5.34 美元。</p>
<p><strong>閲讀我們最新的鐵木藥業股票報告</strong></p>
<h2>鐵木藥業股票表現</h2>
<p>該公司的 50 日移動平均價格為 2.21 美元，200 日移動平均價格為 1.35 美元。該股市值為 5.7865 億美元，市盈率為 22.30，貝塔值為 0.18。</p>
<p>鐵木藥業（NASDAQ:IRWD - 獲取免費報告）最近在 11 月 10 日發佈了季度財報。這家生物技術公司報告每股收益（EPS）為 0.24 美元，超出分析師一致預期的 0.09 美元，超出幅度為 0.15 美元。該季度的營業收入為 1.2206 億美元，而一致預期為 7422 萬美元。鐵木藥業的淨利潤率為 8.70%，股本回報率為負 15.17%。分析師預計鐵木藥業將在本財年發佈 0.1 美元的每股收益。</p>
<h2>機構投資者對鐵木藥業的看法</h2>
<p>大型投資者最近調整了對該股的持有。Integrated Wealth Concepts LLC 在第三季度將其在鐵木藥業的持倉提高了 21.4%。Integrated Wealth Concepts LLC 目前持有 19,295 股該生物技術公司的股票，價值 25,000 美元，此前在上個季度購買了 3,406 股。McAdam LLC 在第一季度購買了鐵木藥業的新股份，價值約 40,000 美元。Vise Technologies Inc.在第三季度購買了鐵木藥業的新股份，價值約 39,000 美元。法國巴黎銀行金融市場在第三季度將其在鐵木藥業的持倉增加了 83.2%。法國巴黎銀行金融市場目前持有 34,331 股該生物技術公司的股票，價值 45,000 美元，此前在上個季度購買了 15,594 股。最後，華僑銀行在第二季度購買了鐵木藥業的新股份，價值約 25,000 美元。</p>
<h2>鐵木藥業公司簡介</h2>
<p>（獲取免費報告）</p>
<p>鐵木藥業公司是一家醫療保健公司，專注於胃腸道（GI）產品的開發和商業化。它在美國、墨西哥、日本、沙特阿拉伯和中國以 LINZESS 的名稱銷售 linaclotide，這是一種用於治療患有便秘型腸易激綜合症或慢性特發性便秘的成人的鳥苷酸環化酶 C（GC-C）激動劑，同時在加拿大和歐洲國家以 CONSTELLA 的名稱銷售。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票超過鐵木藥業</li>
<li>商業服務股票投資</li>
<li>Wolfspeed 剛獲得 6.98 億美元的救助——這改變了一切</li>
<li>什麼是道瓊斯狗策略？概述和示例</li>
<li>優步在達拉斯推出機器人出租車後獲得華爾街最高評級</li>
<li>什麼是認沽期權交易量？</li>
<li>投資者對 Box 的看法完全錯誤——這次由 AI 驅動的反彈剛剛證明了這一點</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在鐵木藥業嗎？</h2>
<p>在你考慮投資鐵木藥業之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而鐵木藥業並不在名單上。</p>
<p>雖然鐵木藥業目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

Ironwood醫藥

<p>Ironwood Pharmaceuticals 的股票下跌了 5%，至 3.5450 美元，交易量較平均水平下降了 86%。分析師的評級各不相同：華爾街 Zen 將評級上調至 “強力買入”，Zacks 將評級下調至 “持有”，Weiss Ratings 則給出了 “賣出” 評級。該股票的平均評級為 “持有”，目標價為 5.34 美元。最近的財報超出預期，每股收益為 0.24 美元，收入為 1.2206 億美元。機構投資者已調整其持股情況，有些增加了持股比例。Ironwood 專注於胃腸道產品，旗下以 LINZESS 和 CONSTELLA 品牌營銷 linaclotide</p>

<p>Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) dropped 5% on Thursday . The stock traded as low as $3.57 and last traded at $3.5450. Approximately 366,023 shares were traded during mid-day trading, a decline of 86% from the average daily volume of 2,568,063 shares. The stock had previously closed at $3.73.</p>
<div class="lb-trans"><p>鐵木藥業公司（NASDAQ:IRWD - 獲取免費報告）週四股價下跌了 5%。該股最低交易價為 3.57 美元，最後交易價為 3.5450 美元。在午盤交易中，約有 366,023 股被交易，較日均交易量 2,568,063 股下降了 86%。該股此前收盤價為 3.73 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Several equities analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Saturday, August 9th. Zacks Research cut Ironwood Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Tuesday, November 4th. Wells Fargo &amp; Company upped their target price on Ironwood Pharmaceuticals from $1.00 to $3.00 and gave the stock an &#34;equal weight&#34; rating in a research report on Tuesday, November 11th. Finally, Weiss Ratings reissued a &#34;sell (d)&#34; rating on shares of Ironwood Pharmaceuticals in a research report on Monday. One equities research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of &#34;Hold&#34; and an average target price of $5.34.</p>
<div class="lb-trans"><p>幾位股票分析師最近對該股發表了看法。華爾街 Zen 在 8 月 9 日的報告中將鐵木藥業的評級從 “持有” 上調至 “強烈買入”。Zacks Research 在 11 月 4 日的研究報告中將鐵木藥業的評級從 “強烈買入” 下調至 “持有”。富國銀行在 11 月 11 日的研究報告中將鐵木藥業的目標價從 1.00 美元上調至 3.00 美元，並給予該股 “等權重” 評級。最後，Weiss Ratings 在週一的研究報告中重新發布了對鐵木藥業的 “賣出（d）” 評級。一位股票研究分析師給予該股 “買入” 評級，六位分析師給予 “持有” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股的平均評級為 “持有”，平均目標價為 5.34 美元。</p>
</div><p><strong>Read Our Latest Stock Report on IRWD</strong></p>
<div class="lb-trans"><p><strong>閲讀我們最新的鐵木藥業股票報告</strong></p>
</div><h2>Ironwood Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>鐵木藥業股票表現</h2>
</div><p>The company's 50 day moving average price is $2.21 and its 200-day moving average price is $1.35. The stock has a market cap of $578.65 million, a P/E ratio of 22.30 and a beta of 0.18.</p>
<div class="lb-trans"><p>該公司的 50 日移動平均價格為 2.21 美元，200 日移動平均價格為 1.35 美元。該股市值為 5.7865 億美元，市盈率為 22.30，貝塔值為 0.18。</p>
</div><p>Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last issued its quarterly earnings data on Monday, November 10th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.15. The business had revenue of $122.06 million during the quarter, compared to the consensus estimate of $74.22 million. Ironwood Pharmaceuticals had a net margin of 8.70% and a negative return on equity of 15.17%. On average, analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>鐵木藥業（NASDAQ:IRWD - 獲取免費報告）最近在 11 月 10 日發佈了季度財報。這家生物技術公司報告每股收益（EPS）為 0.24 美元，超出分析師一致預期的 0.09 美元，超出幅度為 0.15 美元。該季度的營業收入為 1.2206 億美元，而一致預期為 7422 萬美元。鐵木藥業的淨利潤率為 8.70%，股本回報率為負 15.17%。分析師預計鐵木藥業將在本財年發佈 0.1 美元的每股收益。</p>
</div><h2>Institutional Investors Weigh In On Ironwood Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對鐵木藥業的看法</h2>
</div><p>Large investors have recently modified their holdings of the stock. Integrated Wealth Concepts LLC lifted its position in shares of Ironwood Pharmaceuticals by 21.4% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company's stock valued at $25,000 after buying an additional 3,406 shares during the last quarter. McAdam LLC purchased a new stake in Ironwood Pharmaceuticals during the first quarter valued at about $40,000. Vise Technologies Inc. bought a new position in Ironwood Pharmaceuticals during the third quarter worth about $39,000. BNP Paribas Financial Markets increased its stake in shares of Ironwood Pharmaceuticals by 83.2% in the third quarter. BNP Paribas Financial Markets now owns 34,331 shares of the biotechnology company's stock worth $45,000 after purchasing an additional 15,594 shares in the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd bought a new stake in shares of Ironwood Pharmaceuticals in the second quarter valued at approximately $25,000.</p>
<div class="lb-trans"><p>大型投資者最近調整了對該股的持有。Integrated Wealth Concepts LLC 在第三季度將其在鐵木藥業的持倉提高了 21.4%。Integrated Wealth Concepts LLC 目前持有 19,295 股該生物技術公司的股票，價值 25,000 美元，此前在上個季度購買了 3,406 股。McAdam LLC 在第一季度購買了鐵木藥業的新股份，價值約 40,000 美元。Vise Technologies Inc.在第三季度購買了鐵木藥業的新股份，價值約 39,000 美元。法國巴黎銀行金融市場在第三季度將其在鐵木藥業的持倉增加了 83.2%。法國巴黎銀行金融市場目前持有 34,331 股該生物技術公司的股票，價值 45,000 美元，此前在上個季度購買了 15,594 股。最後，華僑銀行在第二季度購買了鐵木藥業的新股份，價值約 25,000 美元。</p>
</div><h2>Ironwood Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>鐵木藥業公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.</p>
<div class="lb-trans"><p>鐵木藥業公司是一家醫療保健公司，專注於胃腸道（GI）產品的開發和商業化。它在美國、墨西哥、日本、沙特阿拉伯和中國以 LINZESS 的名稱銷售 linaclotide，這是一種用於治療患有便秘型腸易激綜合症或慢性特發性便秘的成人的鳥苷酸環化酶 C（GC-C）激動劑，同時在加拿大和歐洲國家以 CONSTELLA 的名稱銷售。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Ironwood Pharmaceuticals</li>
<li>Business Services Stocks Investing</li>
<li>Wolfspeed Just Got a $698 Million Lifeline—Here’s Why That Changes Everything</li>
<li>What is the Dogs of the Dow Strategy? Overview and Examples</li>
<li>Uber Gets a Street-High Upgrade as Robotaxis Roll Out in Dallas</li>
<li>What is Put Option Volume?</li>
<li>Investors Were Dead Wrong About Box—This AI-Driven Comeback Just Proved It</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過鐵木藥業</li>
<li>商業服務股票投資</li>
<li>Wolfspeed 剛獲得 6.98 億美元的救助——這改變了一切</li>
<li>什麼是道瓊斯狗策略？概述和示例</li>
<li>優步在達拉斯推出機器人出租車後獲得華爾街最高評級</li>
<li>什麼是認沽期權交易量？</li>
<li>投資者對 Box 的看法完全錯誤——這次由 AI 驅動的反彈剛剛證明了這一點</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Ironwood Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在鐵木藥業嗎？</h2>
</div><p>Before you consider Ironwood Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資鐵木藥業之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ironwood Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而鐵木藥業並不在名單上。</p>
</div><p>While Ironwood Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然鐵木藥業目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Ironwood Pharmaceuticals（納斯達克股票代碼：IRWD）股價下跌 5% - 現在是賣出的時機嗎？